Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 17,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ELEVATE Clear all
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

NCT04894110
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
Interventions
EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
Biological
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 25, 2026, 7:10 AM EDT
Terminated Phase 2 Interventional

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

NCT03417882
View directory record Official record
Conditions
Metastatic NSCLC
Interventions
GRN-1201 + Pembrolizumab
Biological
Lead sponsor
BrightPath Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 25, 2026, 7:10 AM EDT
Completed No phase listed Observational

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

NCT02946879
View directory record Official record
Conditions
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
Interventions
AAV OPTIRPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 25, 2026, 7:10 AM EDT
Recruiting Phase 2 Interventional

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

NCT05776979
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest

NCT04170062
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia, Dyspnea, Oxygen Inhalation Therapy
Interventions
Nasal Delivery of High-Flow Air and Oxygen Therapy, Nasal Delivery of Oxygen Therapy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
30 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 25, 2026, 7:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

NCT01634646
View directory record Official record
Conditions
Overweight, Elevated Cholesterol
Interventions
Lyzme5
Dietary Supplement
Lead sponsor
Jeff Golini
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
Ad26.RSV.preF-based Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 7:10 AM EDT
Withdrawn Phase 2 Interventional

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

NCT03719560
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Methotrexate, Cytarabine
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 25, 2026, 7:10 AM EDT
Withdrawn Phase 2 Interventional

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

NCT01095523
View directory record Official record
Conditions
Colorectal Carcinoma, Peritoneal Carcinomatosis
Interventions
Laparotomy+ HIPEC +/- CRS
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gum Acacia and Blood Glucose

NCT03716479
View directory record Official record
Conditions
Diet Modification
Interventions
Low Fiber, High Fiber, Placebo/Control
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2

NCT03333161
View directory record Official record
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 15 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus

NCT00308373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin vs Thiazolidinedione (Pioglitazone)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

NCT01441973
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Elotuzumab (BMS-901608; HuLuc63)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • West Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

NCT05650554
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
28
States / cities
Chula Vista, California • Gardena, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Improving Age-Related Cognitive Decline With Exercise in Hypertensive Older Adults

NCT05043454
View directory record Official record
Conditions
Hypertension
Interventions
High Intensity Interval Training (HIIT) Exercise
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 7:10 AM EDT
Recruiting Not applicable Interventional

Evaluation of Grief Therapy Approaches for Bereaved Parents

NCT05142605
View directory record Official record
Conditions
Grief, Bereavement, Cancer
Interventions
Meaning-Centered Grief Therapy, Supportive Psychotherapy, Enhanced Usual Care
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 25, 2026, 7:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Not applicable Interventional Results available

Dietary Approaches to Stop Hypertension for Diabetes

NCT04286555
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Diabetes type2, Type2 Diabetes, Type 2 Diabetes, Type II Diabetes, Hypertension, High Blood Pressure
Interventions
DASH4D diet, comparison diet, higher sodium, lower sodium
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926
View directory record Official record
Conditions
HIV Infections
Interventions
Highly Active Antiretroviral Therapy (HAART), No treatment
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 25, 2026, 7:10 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

NCT06679985
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Casdozokitug, Toripalimab, Bevacizumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 7:10 AM EDT
Not listed Phase 2 Interventional

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

NCT02908035
View directory record Official record
Conditions
Chronic Limb Ischemia
Interventions
Temsirolimus, Saline
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 25, 2026, 7:10 AM EDT